Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO
PODCAST EPISODE 216
With more than $100 million raised in venture capital and three late-stage clinical programs, Oyster Point Pharma is getting a lot done in a short amount of time. In this podcast, CEO and president Jeffrey Nau reveals how the company is working so quickly and ponders what the next major milestone might be.